Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

81. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States

An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States Zhou F J, Reef S, Massoudi M, Papania M J, Yusuf H R, Bardenheier B, Zimmerman L, McCauley M M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A two-dose measles-mumps-rubella (MMR) vaccination programme was compared with no vaccination and with a one-dose MMR vaccination scheme. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis and cost-benefit

Full Text available with Trip Pro

2004 NHS Economic Evaluation Database.

82. Cost-effectiveness of three different vaccination strategies against measles in Zambian children

Cost-effectiveness of three different vaccination strategies against measles in Zambian children Cost-effectiveness of three different vaccination strategies against measles in Zambian children Cost-effectiveness of three different vaccination strategies against measles in Zambian children Dayan G H, Cairns L, Sangrujee N, Mtonga A, Nguyen V, Strebel P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three vaccination strategies against measles were examined. In the first (strategy 1), one dose of measles vaccine was delivered through the routine health care system at 9 months of age. In the second (strategy 2), one dose of measles vaccine was delivered through the routine health care system at 9 months of age

2004 NHS Economic Evaluation Database.

83. Measles: not just another viral exanthem. (PubMed)

Measles: not just another viral exanthem. Measles is the most frequent cause of vaccine-preventable childhood deaths. Infants younger than the recommended age for vaccination are susceptible to the disease, and in developing countries they have a high risk of complications and mortality. Vaccine coverage in excess of 95% interrupts endemic transmission of measles in many countries, but achievement of such coverage almost always requires coordinated supplementary mass vaccination campaigns (...) . There are substantial health gains if countries improve measles vaccine coverage, irrespective of whether or not high coverage is achieved; these gains include much lower measles complication and case fatality rates, long-term interepidemic duration, and possibly non-specific improvements in survival of children. Investigation into the cost-effectiveness of different strategies for measles control, including mass campaigns, two-dose schedules, and young-infant doses, would help countries to formulate control

2003 Lancet

84. The measles-mumps-rubella vaccine (MMR) and autism

The measles-mumps-rubella vaccine (MMR) and autism The measles-mumps-rubella vaccine (MMR) and autism The measles-mumps-rubella vaccine (MMR) and autism Higgins S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Higgins S. The measles-mumps-rubella vaccine (MMR) and autism. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2003: 14 Authors' objectives (...) This aim of this critical appraisal was to assess whether the combined measles-mumps-rubella vaccine (MMR) given according to the Department of Health's immunisation schedule increase the child's risk of developing autism. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Autistic Disorder; Measles-Mumps-Rubella Vaccine /adverse effects Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E

2003 Health Technology Assessment (HTA) Database.

85. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. (PubMed)

Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Females given high-titre measles vaccine (HTMV) have high mortality; diphtheria-tetanus-pertussis (DTP) vaccination might be associated with increased female mortality. We aimed to assess whether DTP or inactivated poliovirus (IPV) administered after HTMV was associated with increased (...) female-male mortality ratio.In three trials from West Africa, 2000 children were randomised to HTMV or control vaccine at 4-5 months of age; a second vaccination was given at age 9-10 months (standard measles vaccine). Children in high-titre groups were given IPV or DTP-IPV. Another 944 children received HTMV as routine vaccination in Senegal.When we compared high-titre and control groups, no difference in mortality between the first and the second vaccination was noted. After the second vaccination

2003 Lancet Controlled trial quality: uncertain

86. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence

Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

87. A population-based study of measles, mumps, and rubella vaccination and autism. (PubMed)

A population-based study of measles, mumps, and rubella vaccination and autism. It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR

2002 NEJM

88. First 5 years of measles elimination in southern Africa: 1996-2000. (PubMed)

First 5 years of measles elimination in southern Africa: 1996-2000. Measles is the leading cause of vaccine-preventable death in Africa. Regional measles elimination is considered feasible using current vaccines and a series of WHO-recommended strategies. We aimed to interrupt transmission of measles, and to use case-based surveillance to show the effect of such interruption.In southern Africa from 1996, seven countries with a total population of approximately 70 million and with relatively (...) high routine vaccination coverage implemented measles elimination strategies. In addition to routine measles immunisation at 9 months of age, these included nationwide catch-up campaigns among children aged 9 months to 14 years, then follow-up campaigns every 3-4 years among children aged 9-59 months, and the establishment of case-based measles surveillance with serological diagnostic confirmation.Nearly 24 million children aged 9 months to 14 years were vaccinated, with overall vaccination

2002 Lancet

89. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. (PubMed)

Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. To investigate whether measles, mumps, and rubella (MMR) vaccination is associated with bowel problems and developmental regression in children with autism, looking for evidence of a "new variant" form of autism.Population study with case note review linked to independently recorded vaccine data.Five health districts in north east London.278 children with core autism

Full Text available with Trip Pro

2002 BMJ

90. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. (PubMed)

Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. We have previously reported that vitamin A supplementation with measles vaccine at age 9 months increases measles-specific antibody concentrations in children at age 18 months compared with placebo. We examined these children when they reached age 6-8 years. Fewer vitamin A-supplemented children had non-protective antibody concentrations (p=0.0095); among children with protective antibody levels, vitamin (...) A-supplemented children tended to have higher geometric mean antibody titres (p=0.09). Thus, simultaneous administration of vitamin A and measles vaccine at age 9 months had a long-term effect on measles-specific antibody levels and may contribute to improved measles control in less-developed countries.

2002 Lancet Controlled trial quality: uncertain

91. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. (PubMed)

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. The administration of the diphtheria and tetanus toxoids and whole-cell pertussis (DTP) vaccine and measles, mumps, and rubella (MMR) vaccine has been associated with adverse neurologic events, including seizures. We studied the relation between these vaccinations and the risk of a first seizure, subsequent seizures, and neurodevelopmental disability in children.This cohort study was conducted

2001 NEJM

92. Evaluating the benefits of increasing measles immunization rates

Evaluating the benefits of increasing measles immunization rates Evaluating the benefits of increasing measles immunization rates Evaluating the benefits of increasing measles immunization rates Zwanziger J, Szilagyi P G, Kaul P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology The study evaluated the effects of increasing measles immunisation rates beyond its baseline value in pre-school children. The comparator was the "do nothing" alternative. Type of intervention Primary prevention (vaccination). Economic study type Cost-utility analysis. Study population The study population comprised pre-school children in urban areas. Setting The setting was the community. The economic study was carried out in the USA. Dates

2001 NHS Economic Evaluation Database.

93. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. (PubMed)

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. More than one dose of measles vaccine is necessary for the sustained control of measles. The aerosol route is thought to be more immunogenic for booster doses than traditional subcutaneous injections, so we did a randomised comparative trial of aerosol and subcutaneous measles vaccines in South African schoolchildren.4327 schoolchildren (aged 5-14 years), assigned (...) by block randomisation of classrooms, received standard titre doses of either Schwarz or Edmonston-Zagreb measles vaccines subcutaneously or by aerosol. Blood samples for antibody assay were collected before vaccination, at 1 month, and 1 year after vaccination. The main endpoints (antibody titres at 1 month and 1 year) were compared between groups.992 children had antibody titre data available for all timepoints. 14 (3.6%) of 385 children who received Edmonston-Zagreb vaccine by aerosol were

2000 Lancet Controlled trial quality: uncertain

94. [Raising the immunization rate in medical students against measles, mumps and rubella at the University of Berne]

[Raising the immunization rate in medical students against measles, mumps and rubella at the University of Berne] Die Erhohung der Immunitatsrate von Medizinstudentinnen und studenten gegen Masern, Mumps und Roteln an der Universitat Bern [Raising the immunization rate in medical students against measles, mumps and rubella at the University of Berne] Die Erhohung der Immunitatsrate von Medizinstudentinnen und studenten gegen Masern, Mumps und Roteln an der Universitat Bern [Raising (...) the immunization rate in medical students against measles, mumps and rubella at the University of Berne] Germann D, Matter L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination of medical students against measles, mumps and rubella

1999 NHS Economic Evaluation Database.

95. Cost-effectiveness of measles outbreak intervention strategies

Cost-effectiveness of measles outbreak intervention strategies Cost-effectiveness of measles outbreak intervention strategies Cost-effectiveness of measles outbreak intervention strategies Shiell A, Jorm L R, Carruthers R, Fitzsimmons G J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Alternative measles outbreak intervention strategies in schools. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population was a single, hypothetical, primary school population of 500 students (aged 5 to 10 years) and their younger siblings. Setting The setting was community, primary care, and hospital. The economic study was carried out in western Sydney, Australia

1998 NHS Economic Evaluation Database.

96. Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence. (PubMed)

Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence. To assess whether antibiotics should be given to all children with measles in communities with a high case fatality rate.Meta-analysis of randomised controlled trials that compared routine antibiotic prophylaxis with no antibiotic treatment or selective treatment of pneumonia or sepsis.Six trials of children admitted to hospital with measles: five in Glasgow, London, or New York between 1939 (...) group. Four of the 764 children given antibiotics died compared with one of the 637 controls (exact odds ratio 4.0, mid-P corrected 95% confidence interval 0.5 to 101.6).The quality of the trials reviewed was poor, and they provide weak evidence for giving antibiotics to all children with measles. Available evidence suggests that, when mortality from measles is high, all children with measles should be treated with vitamin A but antibiotics should be given only if a child has clinical signs

Full Text available with Trip Pro

1997 BMJ

97. Alternative routes of measles immunization: a review

Alternative routes of measles immunization: a review Alternative routes of measles immunization: a review Alternative routes of measles immunization: a review Cutts F T, Clements C J, Bennett J V Authors' objectives To evaluate the potential for non-percutaneous routes of vaccine administration for measles to improve control. Searching The authors state that a literature search was conducted but do not report the names of databases, dates searched or keywords used in the search. Early studies (...) (drops in the eye), oral (drops on sugar, spray on back of oropharynx, or cotton swab), aerosol (nebuliser with reconstituted vaccine placed in a container of crushed ice and attached to a compressor, with dose assumed of 0.145 ml per 30 seconds) and intranasal (swab in anterior nares, drops or bolus instillation in the anterior nares, or large particle spray) administrations of measles vaccine. Participants included in the review Participants were children who were grouped into categories of: 1

1997 DARE.

98. Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence

Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence Shann F Authors' objectives To assess whether prophylactic antibiotics should be given to all children with measles in communities with a high (more than 1%) fatality rate. Searching MEDLINE (...) was searched from 1966 to 1995 using the terms 'measles' plus either 'antibiotic', 'penicillin', 'sulphonamide', 'prospective studies' or 'RCT'. Additional studies were obtained by examining results of previous handsearches of studies of pneumonia in children, in all the journals in the University library from 1935 to 1946. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing routine antibiotic prophylaxis with no antibiotic or with selective

1997 DARE.

99. Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. (PubMed)

Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. To evaluate the impact on clinical recovery and severity of the addition of large doses of vitamin A to the standard treatment for childhood pneumonia.A randomised, double blind, placebo controlled trial.Study children were recruited at a public hospital in Recife, north east Brazil, an area of marginal vitamin A deficiency.472 children aged 6 to 59 months

Full Text available with Trip Pro

1997 BMJ Controlled trial quality: predicted high

100. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. (PubMed)

Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. WHO has recommended vitamin A supplementation for children aged 6 months or older in developing countries at the same time as immunisation. One study has reported significantly lower seroconversion ratios among children who have received vitamin A supplements with measles vaccine at age 6 months. The aim of our study was to assess the effect of vitamin A supplementation (...) on antibody response to measles vaccination at age 9 months, which is the more common age for immunisation in developing countries.In an urban community in Guinea-Bissau, we did a randomised, double-blind, placebo-controlled study of the effect of simultaneous vaccination and vitamin A supplementation in 462 children who received either a two-dose schedule of measles vaccine at the ages of 6 months and 9 months (150 infants) or one dose of measles vaccine at age 9 months (312 infants). Children were

1997 Lancet Controlled trial quality: predicted high